Für diesen Artikel ist leider kein Bild verfügbar.

Bioprocessing of Viral Vaccines

Amine Kamen, Laura Cervera (Herausgeber)

Buch | Softcover

320 Seiten

2024
CRC Press (Verlag)
978-1-032-13551-9 (ISBN)

Artikel merken

This book focuses on cell culture-produced viral vaccines to meet the needs of the rapidly expanding research and development in academia and industry in the field. This book introduces the basic principles of vaccination and the manufacturing of viral vaccines. Bioprocessing of Viral Vaccines, will provide an overview of the advanced strategies needed to respond to the challenges of new and established viral infection diseases. The first few chapters cover the basics of virology and immunology as essential concepts to understand the function and design of viral vaccines. The core of the content is dedicated to process development, including upstream processing and cell culture of viral vaccines, downstream processing, and extensive analytical technologies specific to viral vaccines. Advanced process analytical technologies (PAT) and Quality by Design (QbD) concepts are also introduced in the context of vaccine manufacturing. The case studies included cover inactivated, attenuated vaccines exemplified by influenza vaccines, sub-unit vaccines exemplified by Virus Like Particles (VLPs: HPV vaccines) and sub-unit vaccines (Flublock), vectored vaccines: adenoviruses and Vesicular stomatitis Virus (VSV) vectored vaccines, genomic vaccines (DNA and mRNA) vaccines as developed for COVID-19 response in particular and a review of COVID-19 vaccines approved or in advanced clinical trials. This book is aimed at graduate engineers and professionals in the fields of vaccinology, bioprocessing, and biomanufacturing of viral vaccines.

Amine Kamen is a professor of bioengineering at McGill University, and Canada Research Chair in bioprocessing of viral vaccines. He is a researcher emeritus of the National Research Council of Canada (NRC) where he was employed until early 2014, as head of the Process Development section of the Human Health Therapeutics Portfolio. At NRC, he established one of North America’s largest and most advanced governmental centers for animal cell culture addressing process development and scale-up of biologics. Also, he developed with his team and licensed to industry multiple technology platforms for efficient manufacturing of recombinant proteins and viral vectors and vaccines and led technology transfer to manufacturing sites for clinical evaluation and commercialization. His current research activities focus on uncovering mechanisms associated with cell production of viral vectors and viral vaccines, cell and metabolic engineering, process control and monitoring, and process analytical technologies of high-yield productions of viral vectors for gene delivery and vaccination. He has published over 170 papers in refereed international journals and acts as a consultant for several national and international private and public organizations. Laura Cervera is a Chemical Engineer from Universitat Autònoma de Barcelona (Barcelona, Spain). After graduating she did her PhD in Biotechnology on the topic “Strategies for improving production levels of HIV-1 VLPs by transient transfection of HEK 293 suspension cultures”. Then she moved to McGillUniversity (Montreal, Canada) to pursue her research on VLP production, this time using Insect cells as a platform. She came back to Barcelona to join a project on AAV production for gene therapy applications using HEK 293 cells.

1. Bioprocessing of viral vaccines-Introduction. 2. Introduction to Virology. 3. Principles of immunology. 4. Cell lines for vaccine production. 5. Upstream Processing for Viral Vaccines – General Aspects. 6. Upstream Processing for Viral Vaccines - Process Intensification. 7. Downstream Processing of Viral Vaccines. 8. Analytical, QbD and PAT Applied to Viral Production Processes. 9. Manufacturing of seasonal and pandemic influenza vaccines - a case study. 10. Recombinant vaccines: Gag-based VLPs. 11. Vectored Vaccines. 12. Design and Production of Vaccines Against COVID-19 using Established Vaccine Platforms.

Erscheinungsdatum	21.08.2024
Zusatzinfo	8 Tables, black and white; 2 Line drawings, black and white; 72 Halftones, black and white; 74 Illustrations, black and white
Verlagsort	London
Sprache	englisch
Maße	156 x 234 mm
Gewicht	610 g
Themenwelt	Medizin / Pharmazie ► Physiotherapie / Ergotherapie ► Orthopädie
	Studium ► Querschnittsbereiche ► Infektiologie / Immunologie
	Naturwissenschaften ► Biologie
	Technik ► Medizintechnik
	Technik ► Umwelttechnik / Biotechnologie
ISBN-10	1-032-13551-4 / 1032135514
ISBN-13	978-1-032-13551-9 / 9781032135519
Zustand	Neuware